Abstract Purpose: Variations in biotransformation and elimination of microtubule-binding drugs are a major cause of unpredictable side effects during cancer therapy. Because the orphan receptor, pregnenolone X-receptor (PXR), coordinately regulates the expression of paclitaxel metabolizing and transport enzymes, controlling this process could improve therapeutic outcome. Experimental Design: In vitro RNA-, protein-, and transcription-based assays in multiple cell lines derived from hepatocytes and PXR wild-type and null mouse studies were employed to show the effects of ketoconazole and its analogues on ligand-activated PXR-mediated gene transcription and translation. Results: The transcriptional activation of genes regulating biotransformation and transport by the liganded human nuclear xenobiotic receptor, PXR, was inhibited by the commonly used antifungal ketoconazole and related azole analogs. Mutations at the AF-2 surface of the human PXR ligand-binding domain indicate that ketoconazole may interact with specific residues outside the ligand-binding pocket. Furthermore, in contrast to that observed in PXR (+/+) mice, genetic loss of PXR results in increased (preserved) blood levels of paclitaxel. Conclusions: These studies show that some azole compounds repress the coordinated activation of genes involved in drug metabolism by blocking PXR activation. Because loss of PXR maintains blood levels of paclitaxel upon chronic dosing, ketoconazole analogues may also serve to preserve paclitaxel blood levels on chronic dosing of drugs. Our observations may facilitate new strategies to improve the clinical efficacy of drugs and to reduce therapeutic side effects.
The erratic toxicities of microtubule-binding anticancer drugs can be directly linked in part to the consequences of CYP450-directed drug biotransformation and transporter-dependent elimination (1 -4) . A recent randomized prospective clinical study has shown that CYP3A activity-guided docetaxel dosing results in more uniform drug pharmacokinetics and less toxicity than traditional body surface area -based dosing (5) . For other drugs belonging to this class, inducing or inhibiting either CYP450 or multidrug resistance-1 (MDR1) function has resulted in altered drug metabolism, leading to distinct pharmacokinetic and pharmacodynamic sequelae (6 -8) .
Therefore, approaches to control or ''unify'' metabolism that include both biotransformation and transporter function could result in uniform pharmacokinetics and pharmacodynamics, as well as increased efficacy and predictability of drug treatment.
We and others (9, 10) have previously shown that microtubule-binding drugs activate the pregnenolone X-receptor, PXR. The nuclear xenobiotic receptor PXR and, to a lesser extent, other adopted orphan nuclear receptors (e.g., constitutive androstane receptor, CAR) control genes encoding drug-metabolizing enzymes and transporters at the level of transcription (11, 12) . In mice, paclitaxel activates PXR, induces expression of CYP3A4 and MDR1 gene products, and accelerates its own metabolism, resulting in lowering of blood levels with chronic dosing (13, 14) . Human PXR activation mediated by rifampicin in cell culture induces CYP3A4 (responsible for 3-hydroxy-paclitaxel metabolite), CYP2C8 (responsible for 6-hydroxy-paclitaxel metabolite), MDR1, and MRP-2 (responsible for biliary excretion and intestinal cell efflux of paclitaxel and its metabolites); together, this results in altered paclitaxel pharmacokinetics through metabolic pathways (10, 15, 16) . Biotransforming enzymes and transporters are regulated by PXR such that substrates and/or metabolites of CYP3A4 are coordinately exported in liver and bowel tissues by the MDR1 gene product, and overall metabolic homeostasis is achieved. Drug-drug interactions with regard to paclitaxel therapy can occur by the direct inhibition of the activities of CYP450 enzymes. Drug-drug interactions occur at the level of PXR, where xenobiotics can function as activating agonists (e.g., the hyperforin constituent of St. John's wort) and induce the metabolism of paclitaxel, thereby significantly lowering its blood levels and therapeutic efficacy (17) .
Consequently, we have shown that activated orphan nuclear receptors controlling drug metabolism may be inactivated by ketoconazole, a known inhibitor of CYP450 and UGT1A enzyme activity. We have shown that high doses of ketoconazole inhibit not only enzyme activity but also the transcription of genes regulated by the orphan receptors PXR, CAR, the liver X-receptor (LXR), and the farnesoid Xreceptor (FXR), by limiting associations with the transcriptional coactivator steroid receptor coactivator-1 (SRC-1; ref. 18) . We have proposed that at clinically achievable concentrations, less toxic analogues of ketoconazole can be employed to potently block nuclear receptor-driven transcription and, thus, can be used to modulate the coordinated activation of numerous genes involved in drug metabolism and efflux. Because the majority of anticancer drugs undergo metabolism by multiple enzymes and efflux transporters, transcriptional inhibition of nuclear receptor activity would be expected to generate relatively broad control of drug metabolism pathways, which could improve anticancer drug pharmacokinetics and pharmacodynamics.
In this study, we extend our findings of ketoconazole action on PXR-mediated gene transcription in multiple in vitro hepatocyte and colon cancer cell line models. Furthermore, we provide novel evidence that closely related analogues of ketoconazole, including enilconazole and fluconazole, provide a preliminary base to evaluate structure-activity relationships. We have also shown that human PXR (hPXR) mutants can be designed that preserve ligand binding and activation of the receptor, but are immune to the inhibitory effects of ketoconazole. Such mutants indicate that the activation function 2 (AF-2) region on the surface of the hPXR ligandbinding domain is critical for binding to ketoconazole, suggesting that the azole compounds directly block coactivator binding to the AF-2 site. Finally, we show that inhibiting PXRmediated metabolism of paclitaxel reduces variability of paclitaxel kinetics in mice. We conclude that specific inhibitors of PXR may prevent adverse drug effects and unanticipated PXR-mediated drug metabolism.
Experimental Procedures
Plasmids and reagents. The CYP3A4 luciferase reporter plasmid (À10466 to +53) and PAR-2 in pcDNA3.1 was obtained from Dr. Jonas Uppenberg (Biovitrum, Stockholm, Sweden). Gal4DB-hPXR-LBD, pCMX-hPXR, and Tk-M H100x4-Luc were provided by Dr. Ronald Evans (Salk Institute, La Jolla, CA Cell survival [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Aliquots of 2 to 5 Â 10 3 cells were plated in 96-well plates in triplicate. Twelve hours later, the cells were treated with serial dilutions of each drug. Following incubation for 48 h, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was done as previously described (9) .
Semiquantitative RT-PCR and real-time RT-PCR. Total RNA was isolated using the Qiagen RNeasy Mini kit (Qiagen, Inc., Valencia, CA). To eliminate amplification of contaminating chromosomal DNA in the real-time quantification, the isolated total RNA was treated with RNase-free DNase (Promega, Madison, WI), following the supplier's instructions. Reverse transcription was done using Superscript first strand synthesis system (Invitrogen, Carlsbad, CA). For semiquantitative PCR, one-tenth the reverse transcription (RT) reaction products were subjected to PCR amplification for 35 cycles in a multiplex format. Equal volumes of PCR product were loaded into each well of a 1% ethidium bromide -stained agarose gel as described previously (19) . Real-time PCR for cDNA quantification was done using TaqMan universal PCR master mix and TaqMan probes, using VIC as the 5 ¶ reporter fluorochrome and tetramethylrhodamine (TAMRA) as the 3 ¶ quencher fluorochrome. Simultaneous quantification of the 18S RNA using a kit from ABI Systems (Foster City, CA) allowed for normalization between samples. A standard curve for CYP3A4 cDNA was constructed to ensure linearity in the concentration range studied. The CYP3A4 forward primer sequence was 5 ¶-cattcctcatcccaattcttgaagt-3 ¶, the CYP3A4 reverser primer sequence was 5 ¶-ccactcggtgcttttgtgtatct-3 ¶, and the CYP3A4 probe sequence was 5 ¶-VIC-cgaggcgactttctttcatcctttttacagattttc-TAMRA-3 ¶, all spanning exon junctions, thus preventing amplification of genomic DNA. Amplification was detected and analyzed using the ABI Prism 7700 sequence detector with SDS 2.1 analysis software (Applied Biosystems, Foster City, CA). The relative fold increase in mRNA in samples compared with controls was calculated using the comparative C T method.
Transient transcription and mammalian one-hybrid and twohybrid assays. Cells were split onto 24-well plates at densities of 2 to 8 Â 10 4 cells per well the day before transfection. Transfections were done using the LipofectAMINE reagent (Invitrogen) according to the manufacturer's instructions and as previously described (9) .
Paclitaxel pharmacology studies in C57BL/6 mice. Adult female wild-type PXR (+/+) and PXR-null (À/À) were maintained on standard laboratory chow and were allowed food and water ad libitum (23) . To show the in vivo significance of PXR activation as it relates to paclitaxel metabolism, thirty-six 8-weekold C57BL/6 PXR (+/+) and PXR (À/À) female mice received daily morning i.v. injection with paclitaxel at a dose of 10 mg/kg for five sequential days (20 -22) . Clinical-grade paclitaxel was formulated as described previously (9, 14) . At each time point from the start of injection of paclitaxel on days 1 and 5 (t = pretreatment, 0.25, 0.5, 2, 4, and 8 h), six mice per time point were sacrificed, and all organs, feces, bile, and blood were isolated for further analysis of paclitaxel and its metabolites. Statistical analysis was done with Analyze-It software (Leeds LS27 7WZ, England) using the nonparametric Mann-Whitney U test.
HPLC with tandem mass spectrometric (LC-MS-MS) method for measurement of paclitaxel and its two major metabolites (6a-hydroxypaclitaxel and p-3-hydroxypaclitaxel) concentrations in mouse plasma and tissue. Total paclitaxel (bound and unbound) and its metabolites were extracted from 100 AL of mouse plasma (in this assay, the lower limit is f50 AL) with 2 mL of a mixture of acetonitrile/n-butyl chloride (1:4, v/v), with 20 nmol/L docetaxel used as the internal standard. Separation of paclitaxel, including the internal standard, was achieved on a Waters X-Terra C18 (50 Â 2.1 mm i.d., 3.5 Amol/L) analytic column with a mobile phase consisting of acetonitrile containing 0.1% formic acid (80%) and 2 mmol/L ammonium acetate containing 0.1% formic acid (20%) using isocratic flow at 0.2 mL/min and an overall run time of 5 min. The analytes of interest were monitored by tandem mass spectrometry with electrospray positive ionization at transitions 808 ! 527.2, 870.4 ! 286, 870.4 ! 569, and 854.5 ! 509.4 for paclitaxel, 6a-hydroxypaclitaxel, p-3-hydroxypaclitaxel, and docetaxel, respectively. The lower limit of quantitation of paclitaxel and its metabolites in mouse plasma was 10 ng/mL, corresponding to 0.0117 Amol/L (accuracy, 99.8%). For interassay precision, quality control samples containing 40, 200, and 400 ng/mL (corresponding to 0.05, 0.23, and 0.47 Amol/L) were used, resulting in coefficients of variation of 7.3%, 6.3%, and 2.2% and accuracies of 99.1%, 98.5%, and 100%, respectively. For measurement of paclitaxel and its metabolites in mouse feces and bile, tissue concentrations were standardized by adding PBS to a final concentration of 200 mg/mL. Samples were homogenized on ice until a uniform homogenate was achieved. The tissue homogenate was diluted 1:9 in mouse plasma and 500 AL of the mixture was extracted with 5 mL of a mixture of acetonitrile/n-butyl chloride (1:4, v/v). Paclitaxel and its metabolite concentrations in bile and feces were determined from the calibration curve constructed in mouse plasma.
Results
Donor-and cell type -independent inhibition of ligandmediated activation of CYP3A4 and CYP2B6 gene transcription by ketoconazole. We have previously shown that ketoconazole inhibits hPXR activation (18) . To generalize this result, we determined the effect of ketoconazole on xenobiotic-mediated transcription of CYP450s in another liver-derived cell line, Fa2N-4 (Fig. 1A) . Using real-time reverse transcription-PCR (RT-PCR), we found that rifampicin and paclitaxel, both hPXR agonists, significantly increased the expression of CYP3A4 mRNA when compared with DMSO-treated cells. Treatment of cells with ketoconazole resulted in only a slight increase in CYP3A mRNA expression levels relative to DMSO-treated cells. When ketoconazole was combined with either paclitaxel or rifampicin, however, the CYP3A4 expression was decreased by >90% as compared with cells treated only with paclitaxel or rifampicin, respectively.
To determine if variations in human hepatocyte donors could account for the changes induced by ketoconazole, we carried out quantitative RT-PCR to examine the effect of drugs on CYP450 levels. Human hepatocytes were isolated from three separate liver donors with no prior history of medication use or hepatitis (In Vitro Technologies). These hepatocytes were treated at the same time with either rifampicin, ketoconazole, or both in combination, and CYP3A4 and CYP2B6 mRNA expression were quantitated using RT-PCR. Ketoconazole inhibited rifampicin-mediated induction of CYP3A4 and CYP2B6 genes in a concentration-dependent manner (data not shown). Furthermore, the mean concentrations (IC 50 F SD) of ketoconazole resulting in 50% decrease in rifampicininduced CYP3A4 and CYP2B6 expression were 13.4 F 1.12 and 9.7 F 4.18 Amol/L, respectively (Table 1 ). These results indicate that ketoconazole inhibited the ligand-mediated activation of CYP3A4 and CYP2B6 genes in primary hepatocytes in a donorindependent manner.
Effect of ketoconazole analogues on the rifampicin-mediated activation of hPXR. Ketoconazole belongs to the azole family of compounds, many of which have potent antifungal properties. The above findings indicated that whereas ketoconazole slightly activates the basal level transcriptional activity of hPXR in the absence of a ligand, the compound drastically inhibits hPXR transactivation in the presence of PXR agonists such as rifampicin. We used this property of ketoconazole to identify additional members of the azole family that exhibit a similar activity; such information could be used to elucidate structureactivity relationships. We did transient transcription assays in HepG2 cells using full-length hPXR and its cognate reporter in the presence or absence of various azoles to determine their effect on hPXR-mediated activation (Fig. 1B) . As before, rifampicin activated hPXR 2.7-fold over control (DMSO)-treated cells. The antifungal drugs in the absence of rifampicin showed two distinct properties. Although fluconazole, enilconazole, and ketoconazole showed weak stimulatory activity (Fig. 1B and C) , oxiconazole, miconazole nitrate, miconazole, and R063373 showed inhibitory effects on the basal activity of hPXR. Interestingly, only fluconazole, enilconazole, and ketoconazole inhibited the activation of hPXR to basal level in the presence of paclitaxel. The remaining drugs had profound inhibitory effects on rifampicin-activated hPXR to below the baseline. It is important to note that these drugs alone also had similar effects on the basal activity of hPXR. Collectively, these results indicated that of the azole drugs tested, fluconazole and enilconazole simulated the action of ketoconazole on hPXR and can be termed ''activating antagonists'' because they exhibit weak agonist activities alone but clear antagonist actions in the presence of an established PXR agonist.
Ketoconazole binds hPXR outside the ligand-binding pocket. We have previously shown, using a scintillation-proximity assay that measures the binding of ligands to His-tagged hPXR-LBD, that the IC 50 of the established PXR agonist rifampicin was 8.8 Amol/L. In contrast, the IC 50 for ketoconazole was 74.4 Amol/L. Similarly, the K b (estimated using the Cheng-Prusoff equation) for rifampicin and ketoconazole were 6.3 and 55.3 Amol/L, respectively (18) . These data suggested that biologically active 25 Amol/L concentrations of ketoconazole were unlikely to compete with bona fide ligands for binding within the ligand-binding pocket. To firmly establish whether ketoconazole competed with rifampicin for binding to the ligandbinding pocket or bound to a distinct region on hPXR, we did transient transcription assays with full-length expression construct for hPXR and its cognate reporter. In these experiments, we used two concentrations of rifampicin (10 and 30 Amol/L) to determine the profile of inhibition by ketoconazole.
The data showed a dose response for the effect of ketoconazole on the rifampicin-mediated activation of hPXR because the curves generated in the presence of the two agonist concentrations were essentially parallel ( Fig. 2A) . Note that we did test ketoconazole at concentrations of 100 Amol/L; however, the results were not reliable due to cytotoxicity. This behavior is compatible with noncompetitive inhibition of rifampicin activation by ketoconazole and, hence, is consistent with the idea that ketoconazole doe not interact with the rifampicinbinding site. To corroborate these data, we did mammalian two-hybrid assays using both full-length and ligand-binding domain fusions of hPXR with the VP16 transactivation domain, as previously described. Both assays clearly show that ketoconazole inhibits the rifampicin-induced interaction between hPXR and SRC-1 ( Fig. 2B and C) . Importantly, the magnitude of the effect of ketoconazole on hPXR-SRC-1 interaction is diminished when the NH 2 terminus is truncated, which implies that the preservation of the NH 2 terminus of hPXR is important for ketoconazole action.
We hypothesized that ketoconazole impacts PXR transcriptional regulation by binding at the AF-2 surface rather than in the ligand-binding pocket. To test this hypothesis, several single and double mutations were generated in the AF-2 region of PXR (Fig. 3) . Residues were replaced with corresponding amino acids from the ERa steroid receptor that is not antagonized by ketoconazole. In each case, the single mutants lead to a loss of PXR activity, apparently by introducing structural distortions in the AF-2 surface of the receptor (Fig. 3) . A280W seems to generate a clash with L428 of aAF, which would shift the position of this terminal a-helix (Fig. 3C) and prevent coactivator binding. The replacement of P268 with the nonproline residue H may similarly disrupt the AF-2 surface by reducing the rigidity of the loop between a3 ¶ and a4, thus altering the position of a4. T248E seems to introduce a clash with T422, which would likely shift aAF (up as shown in Fig.  3C ) and lead to a loss in coactivator binding. Finally, replacement of K277 with Q would eliminate the capping of the electronegative helix dipole of aAF by the lysine, which may be critical to the proper positioning of aAF. The corresponding helix in the steroid receptors are one to two turns longer and, thus, cannot be capped by the equivalent side chain.
Significantly, however, the double-mutant T248E/K277Q form of PXR is active but is not susceptible to antagonism by ketoconazole ( Fig. 3B and C) . The recovery of receptor activity is likely due to a synergistic combination of effects: T248E shifts the aAF up and perhaps stabilizes the electropositive NH 2 -terminal helix dipole (Fig. 3C ), but the shorter K277Q residue can accommodate the shift in aAF position to create an AF-2 surface capable of coactivator binding (although not to wildtype levels; see Fig. 3B and C) . Structural considerations also suggest that the elimination of K277 may be responsible for the loss of ketoconazole antagonism. Note that this residue is located close to the side chain of H697 in the nuclear receptor (NR) box 2 of human SRC-1 (Fig. 3C) . Ketoconazole contains an azole ring that may mimic this histidine side chain and compete for coactivator binding. This observation may explain why the antagonism of PXR is agonist dependent: the ordering of the AF-2 surface and critically K277, enhanced by ligand binding, is necessary for ketoconazole binding. A lysine is conserved in this position in all the NRs susceptible to ketoconazole antagonism (PXR, CAR, FXR, LXR), but is replaced by a nonlysine in nuclear receptors that do not respond to this compound (e.g., Q in ERa). Taken together, these data suggest that the AF-2 surface is the likely binding site for ketoconazole.
PXR is an important determinant of paclitaxel blood levels in mice. We and others have previously shown that paclitaxel is a ligand that activates both mouse and human PXR (9, 18) . In PXR (+/+) BALB/c mice, when paclitaxel is administered daily for 5 days i.v. at a dose of 20 mg/kg, the mean area under the curve (AUC) on day 5 compared with day 1 is (86.2 F 5.5 Amol/L h versus 125.6 F 3.8 Amol/L h), mean C max (32.6 F 6.8 Amol/L versus 79.2 F 5.8 Amol/L), and mean t 1/2 b (3.52 F 0.46 h versus 3.13 F 0.18 h; ref. 14). To determine if paclitaxel is inducing its own clearance through the activation of PXR and overexpressing cyp3a11 in mouse liver, we subjected C57BL/6 PXR (+/+) and PXR (À/À) mice to a 5-day course of paclitaxel injections i.v. at a dose of 10 mg/kg. The formulation and schedule of administration of paclitaxel were identical to the previously published report (9) . In PXR (À/À) mice (n = 6 per time points sampled at 0.25, 0.5, 2, 4, and 8 h after paclitaxel injection), using noncompartmental analysis, the mean F SD day 1 and day 5 paclitaxel AUC 0-t were 2,121 F 352 ng/mL h [coefficient of variation (CV), 16 .6%] and 3,459 F 297 ng/mL h (CV, 8.6%), respectively. Similarly, there was a 2.6-fold increase in paclitaxel C t = 15 ¶ on day 5 versus day 1. In PXR (+/+) mice (n = 6 per time points sampled at 0.25, 0.5, 2, 4, and 8 h after paclitaxel injection), the mean F SD day 1 and day 5 paclitaxel AUC 0-t were 2,925 F 924 (CV, 31.6%) and 1,288 F 138 (CV, 10.7%), respectively (P < 0.05). Similarly, in contrast to PXR (À/À) mice, there was a 2.2-fold decrease in paclitaxel C t = 15 ¶ on day 5 versus day 1 in PXR (+/+) mice (Table 2 ). These results suggest that PXR activation is responsible for reduced accumulation of paclitaxel in blood, which may serve as one indicator for drug resistance in mice.
Discussion
We have previously shown that micromolar concentrations of ketoconazole antagonize PXR-dependent gene transcription (9, 14) . In this study, we show that ketoconazole inhibits hPXR in several cell types, and that ketoconazole analogues are readily available to dissect structure-activity relationships to derive less toxic compounds that can inhibit PXR. At the molecular level, we reveal that ketoconazole's effect is a direct consequence of binding to residues outside the ligand binding pocket of PXR and likely in the AF-2 region of the receptor. These are new findings and define a pharmacophore for the interaction of small molecular inhibitors outside the ligandbinding pocket of the nuclear xenobiotic receptor PXR. Preliminary structure-activity relationship studies with ketoconazole analogues suggest that the azole ring may be central to the inhibitory activity of these compounds. Finally, we show that PXR is a key regulator of paclitaxel kinetics, and that loss of PXR activity may prevent the decrease in paclitaxel AUC observed with repetitive dosing.
The clinical implications of our findings are significant. First, this strategy of inhibiting orphan nuclear receptor activation may be used to circumvent adverse drug interactions mediated by xenobiotic activation of PXR. Many drugs in the human pharmacopeia activate hPXR, including some commonly used herbal remedies (24 -29) ; thus, blocking the activation of PXR may prevent drug-drug interactions. Second, as we have shown, loss of PXR could be used to control drug metabolism to desired levels in an appropriate treatment setting. In addition, certain xenobiotics (e.g., paclitaxel) may activate PXR and induce its own clearance upon chronic dosing; however, proof of this phenomenon in humans is lacking (14) . In such situations, CYP450 enzymatic inhibitors will only serve to enhance paclitaxel concentrations that further activate hPXR. It would be beneficial to inhibit hPXR activation, thereby preventing rising xenobiotic concentrations from activating hPXR in an autoregulatory loop. This strategy may yield more predictable steady-state levels of the drug upon chronic dosing. Although there are obvious benefits to inhibiting activated hPXR, in the context of long-term therapeutics, there are risks to this strategy that involve the effect of PXR on direct expression of many different detoxifying genes. This could result in unexpected effects of other toxins and carcinogens ingested, as well as unexpected hypersensitivities to xenobiotics. Therefore, inhibition of activated hPXR will likely have to be intermittently and cautiously approached. Third, there is growing literature on the consequences of hPXR activation as it relates to bone demineralization and the generation of osteomalacia (30, 31) . Therefore, blocking unwanted PXR activation in this context, especially with other therapies like aromatase inhibitors that induce osteomalacia/osteoporosis, can be beneficial. Finally, although unproven, hPXR has been hypothesized to serve as a hormone sensitivity factor in breast cancer (32) . Unwanted activation may lead to reduced effectiveness of aromatase inhibitors or estrogen receptor antagonists. In such situations, it may be beneficial to inhibit tumor PXR activation. Fig. 2 . Ketoconazole inhibits ligand-mediated activation of hPXR and its interactions with SRC-1. Transient transfection assay in (A) CV-1cells to study the effect of ketoconazole on ligand concentration-dependent activation of hPXR. CV-1cells were cotransfected with pCMX-hPXR, CYP3A4 luciferase reporter plasmid (À10466 to +53), and pSV-h-galactosidase control vector for 24 h. Subsequently, the cells were treated with drug(s) as indicated. The RLU/h-gal (relative luciferin light units normalized to h-galactosidase activity) reflects fold increase over untreated (no ketoconazole) controls. Mammalian two-hybrid studies in (B and C) CV-1cells to study the effect of ketoconazole on the interaction of hPXR-LBD and full-length clone with SRC-1. All transfections were normalized for transfection efficiency using pSV-h-galactosidase in the presence or absence of drug(s) as indicated (refer to Materials and Methods). The cells were harvested in equal aliquots at 24 h for luciferase and h-galactosidase assays (for details, see Materials and Methods). All experiments were done at least thrice in triplicates. Columns, mean; bars, SE.
In summary, based on the data presented, we conclude that ketoconazole and selected analogues can antagonize activated forms of the nuclear xenobiotic receptor PXR. The consequence of loss of PXR activity on paclitaxel kinetics has been shown and suggests the clinical utility of PXR inhibitors. Because ketoconazole has pleiotropic effects on cellular targets and it has unpredictable kinetics (33 -37), the optimal drug to inhibit PXR would depend on defining the pharmacophore on PXR, which could lead to the development of more specific drugs.
Finally, we show that the effect of ketoconazole on PXR-driven metabolism is likely due to direct binding to a region on hPXR that is distinct from the ligand-binding pocket. This observation serves as a novel paradigm for inhibitor discovery targeting nuclear receptors.
The implications of our findings, specifically in terms of the control of drug metabolism, are far reaching. In cancer medicine, targeted agents (e.g., epidermal growth factor receptor inhibitors) have surfaced as commonly used therapeutic options for Fig. 3 . Ketoconazole does not abrogate ligand-activated mutant hPXR. Transient transfection assays in (A) HepG2 and (B) NIH3T3 cells to study the effect of ketoconazole on ligand-activated hPXR and its mutants. Cells were cotransfected with pCMV-hPXR.2, CYP3A4 luciferase reporter plasmid (À10466 to +53), and pSV-h-galactosidase control vector for 24 h. Subsequently, the cells were treated with drug(s) as indicated. All transfections were normalized for transfection efficiency using pSV-h-galactosidase in the presence or absence of drug(s) as indicated (refer to Materials and Methods). The cells were harvested in equal aliquots at 24 h for luciferase and h-galactosidase assays (for details, see Materials and Methods). All experiments were done at least thrice in triplicates. Columns, mean; bars, SE. C, close-up of the AF-2 surface of human PXR, as observed in the crystal structure of the LBD of this receptor bound to the NR box motif of SRC-1. Cyan, mutations examined in this paper; magenta, wild-type residues. Red, hydrogen bonding or polar interactions; gray, van der Waals clashes. patients with a variety of malignancies. These small-molecule drugs are rapidly metabolized, and in fact, CYP3A4 is a major enzyme involved in their metabolism (e.g., Iressa, Tarceva, imatinib). Inducers of CYP3A4 (e.g., rifampicin) reduce blood exposure to the parent drug often to subtherapeutic levels. Because drug levels serve to identify both response [e.g., imatinib dose and tumor response type, chronic myelogenous leukemia (200 mg/day) versus gastrointestinal stromal tumors (400 mg/day)] and toxicity (e.g., imatinib steady-state levels and grade 3 edema), modifying drug levels from a single dose by controlling metabolism and unifying the pharmacokinetics-pharmacodynamics would be beneficial. The same principles may apply to epidermal growth factor receptor inhibitors with regard to response-toxicity relationships (e.g., rashpredicting antitumor response). Finally, for cytotoxic drugs, unifying metabolism may lead to drug exposures that normalize toward the population mean. Fewer outliers would translate to less unpredictability in terms of drug pharmacokinetics-pharmacodynamics and perhaps to better compliance and overall outcomes. For all these reasons, identifying small molecules that are themselves inert in terms of cellular toxicity but are potent in blocking PXR-driven drug metabolism would serve as a critical novel tool to apply to a wide variety of therapeutic settings.
